Why Regencell Bioscience Holdings (NasdaqCM:RGC) is in Focus Right Now

Regencell Bioscience Holdings (NasdaqCM:RGC) has filed a US$500 million follow on equity offering of common stock as an at the market program, shortly after registering a shelf for its ordinary shares.

The equity offering headlines come after a sharp shift in sentiment, with a 7 day share price return of 32.15% and a 30 day share price return of 32.03%, set against a 90 day share price return of a 6.66% decline and a very large 1 year total shareholder return off a low base. Taken together, these figures suggest that short term momentum has picked up while longer term risks and expectations remain in sharp focus.

If this kind of fast moving story has your attention, it can be useful to broaden the watchlist and see what else is out there via our screener of 20 top founder-led companies

With Regencell posting sharp recent gains, reporting no revenue and a loss of US$3.58m, and now lining up a US$500m at-the-market program, you have to ask: is there genuine mispricing here, or is the market already baking in future growth?

Preferred Price-to-Book of 3,136.7x: Is it justified?

On the latest figures, Regencell Bioscience Holdings trades on a P/B of 3,136.7x, compared with a US Pharmaceuticals peer average of 25.9x and an industry average of 2.3x.

The P/B ratio compares the market value of the company to its book value, essentially what shareholders would get if all assets were sold and liabilities paid. For early stage or pre revenue businesses, P/B can move sharply because the equity base is small while the market value is highly sensitive to shifts in sentiment.

With no revenue, a reported loss of $3.58m and a negative return on equity of 73.75%, such a high P/B suggests the market is placing a very large premium on potential future outcomes rather than current financials. For some investors, this raises a question about how much future success is already reflected in the current $30.83 share price.

Compared with both its direct peers on 25.9x and the broader US Pharmaceuticals industry on 2.3x, Regencell’s 3,136.7x P/B stands out as extremely rich on this simple yardstick.

Result: Price-to-book of 3,136.7x (OVERVALUED)

However, investors also face execution risk around Regencell’s Traditional Chinese medicine pipeline, as well as potential dilution from the US$500m at-the-market equity program.

Next Steps

Given how mixed this picture is, it makes sense to look past the headlines, review the underlying data yourself, and decide where you stand based on the 3 important warning signs

Looking for more investment ideas?

If this situation has sharpened your thinking, do not stop here. The right tools can help you spot other opportunities before they move out of reach.

• Target resilient balance sheets by scanning companies on the solid balance sheet and fundamentals stocks screener (40 results) that pair financial strength with fundamental support.
• Hunt for mispriced quality by reviewing the 62 high quality undervalued stocks that highlight stocks combining solid cash flows with supportive balance sheets.
• Spot potential income ideas early by checking the 13 dividend fortresses featuring companies with higher yielding payouts.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.